Seeking Alpha

FDA panel discusses Merck's Vorapaxar

  • A panel of external FDA advisers is meeting to discuss whether to approve recommending Merck's (MRK -0.8%) Vorapaxar drug for preventing drug clots.
  • On Monday, the agency said in a preliminary review that the treatment should be authorized following "robustly positive" clinical trial results.
  • Vorapaxar, which Merck plans to sell under the brand name Zontivity, is designed to prevent heart-related deaths, heart attacks and strokes in patients who have recently suffered a heart attack but not a stroke.
  • You can follow updates from the meeting on Twitter here.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: